Lumida
/SDGR
⌘K
Schrodinger Inc

Schrodinger Inc

SDGR
$19.02USD+1.17%+0.22 today

MARKET CAP

1.4B

P/E (TTM)

FWD P/E

DAY RANGE

$19 – $19

52W RANGE

$11
$23

AI Summary

Stalk
Sell NowMedium

SDGR has broken key early-September consolidation support, closing below the rising 9EMA and 20EMA, signaling that buyers can no longer absorb supply and suggesting potential for accelerated downside. Medium-term bias shifts to bearish given the Support Failure pattern, and short-term timing is unfavorable with rejection at EMAs. Execution focuses on sell-side participation into any bounce toward the former support zone near mid-19s, with invalidation on a reclaim and acceptance back above the 9EMA/20EMA area.

  • ACV up 27% YoY to $29.6M; FY ACV guide $218–228M
  • Q2 total revenue $58.9M; drug discovery rev rose to $23M
  • Negative earnings yield and weak profitability factors signal low returns
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$137.9M$181.0M$216.7M$207.5M$255.9M
YoY %+27.6%+31.2%+19.7%-4.2%+23.3%
P / Sales17.8x7.2x12.2x6.8x5.1x
EV / Sales18.4x8.0x12.6x8.0x5.6x
Gross Profit, Adj.$65.6M$101.0M$140.7M$132.1M$142.6M
YoY %+3.4%+54.0%+39.3%-6.1%+8.0%
Margin %47.6%55.8%64.9%63.6%55.7%
EV / Gross Profit38.7x14.4x19.4x12.5x10.1x
EBITDA, Adj.$-108.6M$-142.5M$-171.9M$-203.1M$-160.9M
YoY %-109.2%-31.2%-20.7%-18.2%+20.8%
Margin %-78.7%-78.7%-79.3%-97.9%-62.9%
EV / EBITDA-23.4x-10.2x-15.9x-8.2x-9.0x
EBIT$-111.4M$-146.8M$-177.4M$-209.3M$-166.9M
YoY %-82.9%-31.7%-20.9%-17.9%+20.3%
Margin %-80.8%-81.1%-81.9%-100.8%-65.2%
EV / EBIT-22.8x-9.9x-15.4x-7.9x-8.7x
Net Income$-100.4M$-149.2M$40.7M$-187.1M$-103.3M
YoY %-310.4%-48.6%+127.3%-559.5%+44.8%
Net Margin-72.8%-82.4%18.8%-90.2%-40.4%
EPS (GAAP)-$1.42-$2.10$0.54-$2.57-$1.41
YoY %-246.3%-47.9%+125.7%-575.9%+45.1%